Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026.

Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates.

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.

The company is advancing the treatment into a Phase 3 study with results expected in 2026.

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.